Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital …

September 9, 2015 - als

BALTIMORE LOS ANGELES BOSTON–(BUSINESS WIRE)–Johns Hopkins University’s Robert Packard Center for ALS Research,
Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the
Massachusetts General Hospital Neurological Clinical Research Institute
now announced a launch of an Amyotrophic Lateral Sclerosis (ALS)
investigate plan of Answer ALS, a largest singular concurrent and
extensive bid to finish ALS.

ALS is a devastating, on-going and deadly neuromuscular illness for
that there is no effective treatment. In ALS, light lapse of
engine haughtiness cells in a mind and spinal cord causes increased
problem swallowing and breathing, and eventually leads to paralysis.
A new chairman is diagnosed with ALS any 90 mins in a United States.

The idea of Answer ALS is to:

  • Discover what causes ALS;
  • Develop worldly tellurian dungeon models to know ALS and screen
    for drug and mobile therapies;
  • Initiate individualized ALS therapy programs formed on patients’ own
    mobile information from mind cells;
  • Discover therapies that could almost slow, hindrance and ultimately
    heal ALS; and
  • Provide all collected information giveaway for worldwide use by clinicians,
    scientists and pharma to fast allege therapeutics.

“This is an rare proceed to bargain and defeating
disease,” pronounced Dr. Jeffrey Rothstein, Director of a Brain Science
Institute and a Robert Packard Center for ALS Research during Johns
Hopkins University and a Executive Director of Answer ALS. “This
plan will move together world-renowned ALS investigate scientists to
work opposite an assertive timeline for understanding, treating and
eventually anticipating a heal for this disease. The estimable initial
appropriation from these inexhaustible supporters is a vicious step brazen in our
bid to yield wish to those influenced by ALS.”

“We are mixing immeasurable data, extensive biological analytics,
record and scholarship in a proceed that would not have been probable a
decade ago,” pronounced Clive Svendsen, PhD, Director of a Regenerative
Medicine Institute during Cedars-Sinai Medical Center and Co-Director of
Answer ALS. “What is so sparkling and vicious is that all of this data
will be done publicly accessible with free, open entrance to a ALS
investigate community, so that we can make faster and larger strides
together to find a heal for this disease.”

“By leveraging clinical and representation information collection systems built by the
Northeast ALS Consortium (NEALS) with a support of a ALS Association
and ALS Finding a Cure Foundation, enrollment of participants and
pity of information and samples will be accelerated,” pronounced Merit Cudkowicz,
MD, Chief of Neurology and Co-Director of a Neurological Clinical
Research Institute during Massachusetts General Hospital and Co-Director of
Answer ALS. “In partnership with a patients, their families and our
NEALS investigate ambassadors, this collaborative plan will accelerate
anticipating treatments for people with ALS.”

The plan will emanate a largest and many extensive substructure of
ALS information ever amassed, encompassing clinical, chemical, genetic,
protein, chronological and biological information from an huge sampling of ALS
patients in a United States. In partnership with appurtenance learning
and immeasurable information technology, a information will be mined to expose ALS causes,
subtypes, pathways left badly and drug targets. This will settle a
immeasurable and vicious substructure for new clinical trials, rise new ways
to specify patients to brand specific druggable pathways and
subtype biomarkers and illness pathophysiology to assist not usually in early
diagnosis of a disease, though also to guard a efficiency of newly
grown treatments.

This investigate plan also could potentially yield deeper
bargain of Alzheimer’s, Parkinson’s and other neurodegenerative

Funded by Committed Private Donors

Answer ALS originated as a outcome of a 2013 ALS Team Gleason Summit,
that brought together heading researchers, patients, caregivers and
advocates. One of a many poignant outcomes of a Summit was a plan
to urgently find a diagnosis or heal for ALS. The eventuality was spearheaded
by former NFL actor Steve Gleason who lives with ALS and founded the
ALS advocacy group, Team Gleason.

A appropriation bid led by a Leandro P. Rizzuto Foundation and a Robert
Packard Center for ALS Research has resulted in $20 million lifted for
Answer ALS so far. The initial stakeholder funders are a National
Football League, a PGA TOUR, ALS Finding a Cure (a plan of the
Leandro P. Rizzuto Foundation), Travelers, The Fishman Family and The
Bari Lipp Foundation.

Their appropriation will launch this investigate plan in a entrance months. A
sum of approximately $25 million is indispensable to finish a initial phase
of a program. Funding will be concurrent by a Robert Packard
Center for ALS Research during Johns Hopkins University and Massachusetts
General Hospital for a ALS Finding a Cure Foundation.

“I’ve always said, to change a march of this disease, as a community,
we would have to be bigger than ALS,” pronounced Gleason. “I trust that if
we dedicate to this effort, on this scale, we will have suggestive results
in a lifetime. Reaching this volume of fundraising success in such a
brief volume of time is inspiring. we dared able people to step
adult and assistance solve ALS. These committed people and organizations
have resolutely answered that challenge.”

“The harmful impact of ALS was entirely satisfied by a PGA TOUR’s
extended family in 2004 when it tragically claimed a lives of caddie
Bruce Edwards and member Jeff Julian, only months apart,” pronounced PGA TOUR
Commissioner Tim Finchem. “And now we learn that one of a dear friends
and longtime associates, Jay Fishman of Travelers, has been diagnosed
with ALS. We are intensely unapproachable to lend a support to this concerted
bid to anticipating a heal for this terrible disease.”

Jay Fishman, Chairman and CEO of Travelers, who recently announced his
ALS diagnosis, said, “After being diagnosed with ALS, we looked for the
many assertive plan with a biggest probability of yielding
formula by fast benchmarks and milestones. This was that project.”

Fishman continued, “The passion, joining and collaborative suggestion of
this consultant organisation of scientists and clinicians are zero brief of
remarkable. we am deeply tender by their believe and dedication.”

“To accelerate growth of treatments for people with ALS, we brought
together a conspicuous group of scientists, a loyal powerhouse, to answer
one of a hardest and many vicious questions in a biology of ALS,”
pronounced Peter Foss, President of a ALS Finding a Cure Foundation, and
General Manager of a GE/NFL TBI investigate project. “We support open,
collaborative scholarship that tackles elemental therapy-driven questions
and includes real-time village pity of data. This is a best
proceed to accelerate anticipating a heal for all people with ALS.”

Driven by a Collaborative Team of Leading ALS Research Scientists and

This Answer ALS investigate plan will be destined by Dr. Jeffrey
Rothstein, Dr. Clive Svendsen and Dr. Merit Cudkowicz.

Program group leaders include:

  • Clinical – Nicholas Maragakis, Johns
    Hopkins University and James Berry, Massachusetts General Hospital,
    Harvard University;
  • iPSC – Dhruv Sareen, Cedars-Sinai;
  • Omics – Leslie Thompson, University of
    California Irvine; and
  • Data Analysis – Steven Finkbeiner,
    Gladstone Institutes/UCSF and Ernest Frankel, Massachusetts Institute
    of Technology.

Dedicated to Aggressive, Comprehensive Research

Specifics of Answer ALS’s investigate module include:

  • Large Patient Population – Urgently evaluating a really large
    studious race (at slightest 1,000+ ALS patients) and collecting
    extensive and longitudinal clinical information from any participant
    by 5-7 rarely experienced, geographically diversified ALS clinics
    over several years.
  • Real-Time 24/7 Clinical Data – Utilizing industry-leading,
    wearable computing record to extensively magnitude participants’
    illness believe and regulating this expanded information to form algorithms
    that will mix health, biological and chronological data.
  • Generate iPSC-derived Brain Cells – Generating induced
    pluripotent dungeon lines (iPSC) from any studious and regulating these to
    emanate thousands of new and opposite mind dungeon lines (e.g., motor
    and cortical neurons, astroglia, oligodendroglia).
  • Comprehensive Biological and Clinical Data Sets – Performing
    a many extensive biological analytics ever due on those
    patients’ iPSC-derived mind cells, including whole genome,
    epi-genome, RNA, protein, mobile metabolism and robotic imaging
    analyses of tangible flourishing tellurian ALS patients’ mind cells.
  • National Collaborative Consortium – Amassing a collaborative
    group of a world’s experts on iPSC cells, DNA, RNA and protein
    analytics, clinical indices, clinical hearing pattern and, most
    importantly, immeasurable information analytics.
  • Large Data Technology and Analytics – Bringing together some of
    a heading experts on immeasurable information sets to occupy appurtenance learning
    approaches to ALS.

To learn some-more about a Answer ALS module or to get involved, please
or call 1-800-490-2375.

About a Robert Packard Center for ALS Research during Johns Hopkins

The Robert Packard Center for ALS Research during Johns Hopkins is a only
general collaborative systematic operation dedicated only to
restorative a disease. The Center is singular in a proceed to fighting
ALS, a engine neuron disease, in that it combines and facilitates
academic, clinical and systematic partnership and ALS investigate with
fundraising for a growth of new illness models, new treatments
and to anticipating a cure. Founded in 2000, a Packard Center brings ALS
scientists from all over a universe together to mix army in ALS
research. Each month, brainstorming sessions brand earnest research
approaches and weigh progress. Packard grantees, their post-docs and
lab staff, Packard systematic advisors, collaborating clinicians and a
bare-bones executive staff work together in this dedicated network.
The immeasurable infancy of collection to know ALS and to learn new
therapies and new healing possibilities are grown by Packard Center
researchers. For some-more information about a Packard Center and its
stream investigate portfolio, greatfully revisit their website:

About Cedars-Sinai Board of Governors Regenerative Medicine Institute

Cedars-Sinai is a personality in providing high-quality healthcare
encompassing primary care, specialized medicine and research. Since
1902, Cedars-Sinai has grown to accommodate a needs of one of a most
different regions in a nation, environment standards in peculiarity and
innovative studious care, research, training and village service.
Today, Cedars-Sinai is famous for a inhabitant caring in transforming
medical for a advantage of patients. Cedars-Sinai houses a Board of
Governors Regenerative Medicine Institute that specializes in the
prolongation of prompted pluripotent branch cells for both displaying and
treating tellurian diseases such as ALS. For some-more information, greatfully visit:

About a Massachusetts General Hospital (MGH) ALS Program

Founded in 1811, Massachusetts General Hospital (
is a strange and largest training sanatorium of Harvard Medical
School. Since 1984, Massachusetts General Hospital has been providing
a highest-quality caring to people with amyotrophic lateral
sclerosis (ALS), along with entrance to a latest treatments and research
opportunities for patients, by a MGH ALS Multidisciplinary Clinic
As a clinical coordination core for ALS clinical trials, a MGH ALS
Team and a Neurological Clinical Research Institute (
are famous for their caring and creation in bringing treatments
brazen well and rapidly to trials for people with ALS.
Partnered with scientists during MGH and via a world, a MGH ALS
group is committed to improving a health and caring of people and
families with ALS.

About Team Gleason

The Gleason Initiative Foundation, famous as Team Gleason, is a
free 501c3 non-profit house founded by former NFL player
Steve Gleason who was diagnosed with ALS in 2011. Team Gleason’s mission
is to assistance yield people with neuromuscular diseases or injuries
with heading corner technology, apparatus and services; to emanate a global
review about ALS to eventually find solutions and an finish to the
disease; and, to lift open recognition toward ALS by providing and
documenting unusual life adventures for people with muscular
diseases or injuries. For some-more information, greatfully visit:

About ALS Finding a Cure® Foundation

Formed in open of 2014, a solitary purpose of a ALS Finding a Cure®
Foundation is appropriation investigate to find a cure. The foundation’s idea is
to interpret appropriation into cutting-edge growth tools, yield an
open height for neurological investigate material, know disease
heterogeneity to rise treatments and foster early showing for
those influenced by ALS. To mangle down barriers to anticipating a heal for
people with ALS, we support collaborative scholarship by partnerships,
including with General Electric, a ALS Association and now Answer ALS.
General Electric Healthcare, one of a many vicious collaborators,
has grown breakthrough record to improved know a mind and
spinal cord. In partnership, we move their record and believe to
bargain ALS and accelerating therapy development. Our group of
researchers is led by a Chief Medical Officer Dr. Merit Cudkowicz and
a substructure is overseen by Peter N. Foss. ALS Finding a Cure® is a
module of a Leandro P. Rizzuto Foundation. We are unapproachable to report
that 100% of donations goes directly to appropriation investigate and that all
outward donations to ALS Finding a Cure® are now matched by The
Leandro P. Rizzuto Foundation. ALS Finding a Cure® is desirous by and is
a reverence to Christie Rizzuto, who was diagnosed with ALS in 2009 during the
age of 41. It is Christie, and a many others like her, who expostulate our
work. For some-more information, greatfully revisit

source ⦿

More als ...

› tags: als /